应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
09939 开拓药业-B
交易中 03-11 13:59:29
1.120
-0.010
-0.88%
最高
1.150
最低
1.100
成交量
39.35万
今开
1.110
昨收
1.130
日振幅
4.42%
总市值
5.01亿
流通市值
5.01亿
总股本
4.47亿
成交额
43.74万
换手率
0.09%
流通股本
4.47亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
【QDII基金双料冠军突然卸任全部在管产品】 南方基金日前发布公告称，基金经理王士聪因个人原因卸任其在管的全部基金产品，这些产品有多只进入2025年以来全市场QDII十五强、十强、三强，涉及科技、消费、医药等多个赛道基金。值得一提的是，王士聪是最近十年间，公募行业少数罕见的连续两次获得年度公募QDII冠军的基金经理，分别为2020年的101.68%以及2024年的51.22%。
金融界 · 12:58
【QDII基金双料冠军突然卸任全部在管产品】 南方基金日前发布公告称，基金经理王士聪因个人原因卸任其在管的全部基金产品，这些产品有多只进入2025年以来全市场QDII十五强、十强、三强，涉及科技、消费、医药等多个赛道基金。值得一提的是，王士聪是最近十年间，公募行业少数罕见的连续两次获得年度公募QDII冠军的基金经理，分别为2020年的101.68%以及2024年的51.22%。
QDII基金双料冠军突然卸任全部在管产品
美港电讯 · 12:57
QDII基金双料冠军突然卸任全部在管产品
仁和药业出资800万元成立江西仁和医药投资有限公司，持股80%
金融界 · 12:18
仁和药业出资800万元成立江西仁和医药投资有限公司，持股80%
安徽柏拉阿图医药科技有限公司药品申请临床试验默示许可获受理
金融界 · 12:18
安徽柏拉阿图医药科技有限公司药品申请临床试验默示许可获受理
南京征祥医药有限公司药品申请临床试验默示许可获受理
金融界 · 12:18
南京征祥医药有限公司药品申请临床试验默示许可获受理
上海海思盛诺医药科技有限公司药品申请临床试验默示许可获受理
金融界 · 12:18
上海海思盛诺医药科技有限公司药品申请临床试验默示许可获受理
华测检测：医药医学是华测重点布局的领域之一提供全链条服务
证券之星 · 12:06
华测检测：医药医学是华测重点布局的领域之一提供全链条服务
奥克股份：公司医药级聚乙二醇产品质量领先，全系产品通过了EXCiPACT认证
证券之星 · 11:37
奥克股份：公司医药级聚乙二醇产品质量领先，全系产品通过了EXCiPACT认证
同源康医药-B盘中异动 急速下跌5.20%报33.700港元
市场透视 · 09:33
同源康医药-B盘中异动 急速下跌5.20%报33.700港元
“头对头”击败阿斯利康，同源康医药选择的小众赛道，尚无专属获批药物
钛媒体 · 00:00
“头对头”击败阿斯利康，同源康医药选择的小众赛道，尚无专属获批药物
“头对头”击败肺癌药物明星品种？同源康医药早盘一度涨超50%
澎湃 · 03-10 22:18
“头对头”击败肺癌药物明星品种？同源康医药早盘一度涨超50%
吉林敖东：公司核心业务与吉林省“医药强省”战略方向一致
证券之星 · 03-10 20:51
吉林敖东：公司核心业务与吉林省“医药强省”战略方向一致
【海王生物：NEP018片获药物临床试验批准】海王生物公告，全资子公司海王医药研究院的NEP018片近日获得国家药监局核准签发的《药物临床试验批准通知书》。通知书指出，经审查，NEP018片临床试验申请符合药品注册有关要求，同意其在晚期恶性实体瘤中开展临床试验。NEP018片是海王医药研究院自主研发的新型肿瘤靶向小分子激酶抑制剂，对设计靶点有良好选择抑制活性，针对胃肠道肿瘤具有良好的抑制作用。
金融界 · 03-10 16:27
【海王生物：NEP018片获药物临床试验批准】海王生物公告，全资子公司海王医药研究院的NEP018片近日获得国家药监局核准签发的《药物临床试验批准通知书》。通知书指出，经审查，NEP018片临床试验申请符合药品注册有关要求，同意其在晚期恶性实体瘤中开展临床试验。NEP018片是海王医药研究院自主研发的新型肿瘤靶向小分子激酶抑制剂，对设计靶点有良好选择抑制活性，针对胃肠道肿瘤具有良好的抑制作用。
华昊中天医药-B03月10日主力净流出15万元 散户资金买入
市场透视 · 03-10 16:16
华昊中天医药-B03月10日主力净流出15万元 散户资金买入
开拓药业-B03月10日主力净流出32万元 散户资金买入
市场透视 · 03-10 16:15
开拓药业-B03月10日主力净流出32万元 散户资金买入
健康元：公司接入DeepSeek全面推进AI在医药全链条的应用
证券之星 · 03-10 16:07
健康元：公司接入DeepSeek全面推进AI在医药全链条的应用
“能源+医药”双线布局，美锦能源“跨界救火”迎涨停
格隆汇 · 03-10 15:38
“能源+医药”双线布局，美锦能源“跨界救火”迎涨停
3月10日润达医疗涨停分析：医药商业，医疗耗材供应链SPD，互联网医疗概念热股
证券之星 · 03-10 15:31
3月10日润达医疗涨停分析：医药商业，医疗耗材供应链SPD，互联网医疗概念热股
A股收评：三大指数小幅调整，创业板指跌0.25%，培育钻石、医药商业板块爆发
格隆汇 · 03-10 15:27
A股收评：三大指数小幅调整，创业板指跌0.25%，培育钻石、医药商业板块爆发
A股医药商业板块午后活跃，老百姓涨停，海王生物、健之佳、人民同泰、漱玉平民、益丰药房等涨幅靠前。
美港电讯 · 03-10 13:36
A股医药商业板块午后活跃，老百姓涨停，海王生物、健之佳、人民同泰、漱玉平民、益丰药房等涨幅靠前。
加载更多
公司概况
公司名称：
开拓药业-B
所属市场：
SEHK
上市日期：
--
主营业务：
开拓药业有限公司是一家临床阶段新药开发商，专注于研究癌症药物及其他雄激素受体（AR）相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌（mCRPC）的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。
发行价格：
--
{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.12,"timestamp":1741672355911,"preClose":1.13,"halted":0,"volume":393500,"delay":0,"floatShares":447499600,"shares":447499600,"eps":-2.6489495904909885,"marketStatus":"交易中","change":-0.01,"latestTime":"03-11 13:59:29","open":1.11,"high":1.15,"low":1.1,"amount":437435,"amplitude":0.044248,"askPrice":1.13,"askSize":1500,"bidPrice":1.12,"bidSize":45000,"shortable":0,"etf":0,"ttmEps":-2.292544341702921,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1741680600000},"marketStatusCode":2,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":1.13,"openAndCloseTimeList":[[1741656600000,1741665600000],[1741669200000,1741680000000]],"volumeRatio":0.331044,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2518547147","title":"【QDII基金双料冠军突然卸任全部在管产品】 南方基金日前发布公告称，基金经理王士聪因个人原因卸任其在管的全部基金产品，这些产品有多只进入2025年以来全市场QDII十五强、十强、三强，涉及科技、消费、医药等多个赛道基金。值得一提的是，王士聪是最近十年间，公募行业少数罕见的连续两次获得年度公募QDII冠军的基金经理，分别为2020年的101.68%以及2024年的51.22%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518547147","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518547147?lang=zh_cn&edition=full","pubTime":"2025-03-11 12:58","pubTimestamp":1741669098,"startTime":"0","endTime":"0","summary":"南方基金日前发布公告称，基金经理王士聪因个人原因卸任其在管的全部基金产品，这些产品有多只进入2025年以来全市场QDII十五强、十强、三强，涉及科技、消费、医药等多个赛道基金。值得一提的是，王士聪是最近十年间，公募行业少数罕见的连续两次获得年度公募QDII冠军的基金经理，分别为2020年的101.68%以及2024年的51.22%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11125848651676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","BK1574","159938","09939","BK1161"],"gpt_icon":0},{"id":"2518216754","title":"QDII基金双料冠军突然卸任全部在管产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2518216754","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518216754?lang=zh_cn&edition=full","pubTime":"2025-03-11 12:57","pubTimestamp":1741669054,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["159938","BK1515","BK1161","BK1574","09939"],"gpt_icon":0},{"id":"2518751210","title":"仁和药业出资800万元成立江西仁和医药投资有限公司，持股80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518751210","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518751210?lang=zh_cn&edition=full","pubTime":"2025-03-11 12:18","pubTimestamp":1741666708,"startTime":"0","endTime":"0","summary":"天眼查工商信息显示，近日，仁和药业股份有限公司出资800万元成立江西仁和医药投资有限公司，持股80%，所属行业为资本市场服务。资料显示，江西仁和医药投资有限公司成立于2025年3月10日，法定代表人为朱凌云，注册资本1000万人民币，公司位于宜春市，以自有资金从事投资活动，企业管理咨询，企业管理（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/11121848651237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1515","BK0239","09939","000650","BK0097","BK1574","159938","BK0188"],"gpt_icon":0},{"id":"2518751295","title":"安徽柏拉阿图医药科技有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2518751295","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518751295?lang=zh_cn&edition=full","pubTime":"2025-03-11 12:18","pubTimestamp":1741666695,"startTime":"0","endTime":"0","summary":"3月11日，据CDE官网消息，安徽柏拉阿图医药科技有限公司联合申请药品“PA9159鼻喷雾剂”，获得临床试验默示许可，受理号CXHB2400308。安徽柏拉阿图医药科技有限公司，成立于2018年，位于宿州市，是一家以从事研究和试验发展为主的企业。主要股东信息显示，安徽柏拉阿图医药科技有限公司由浙江柏拉阿图医药科技有限公司持股60%、江山泰鼎企业管理有限公司持股20%、宿州市新区建设投资集团有限公司持股20%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/11121848651303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","03347","159938","BK1583","09939","BK1515","BK1161","BK1576","BK1574"],"gpt_icon":0},{"id":"2518751260","title":"南京征祥医药有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2518751260","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518751260?lang=zh_cn&edition=full","pubTime":"2025-03-11 12:18","pubTimestamp":1741666695,"startTime":"0","endTime":"0","summary":"3月11日，据CDE官网消息，南京征祥医药有限公司联合申请药品“ZX-7101A片”，获得临床试验默示许可，受理号CXHB2400307。公示信息显示，药品“ZX-7101A片”适应症：成人和12岁及以上青少年接触流感患者后的暴露后预防。南京征祥医药有限公司，成立于2020年，位于南京市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，南京征祥医药有限公司共对外投资了3家企业，知识产权方面有商标信息14条，专利信息17条，此外企业还拥有行政许可15个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/11121848651302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09939","03347","BK1515","BK1161","BK1583","BK1574","159938","BK1576","BK1141"],"gpt_icon":0},{"id":"2518751212","title":"上海海思盛诺医药科技有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2518751212","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518751212?lang=zh_cn&edition=full","pubTime":"2025-03-11 12:18","pubTimestamp":1741666695,"startTime":"0","endTime":"0","summary":"3月11日，据CDE官网消息，上海海思盛诺医药科技有限公司联合申请药品“HSK44459片”，获得临床试验默示许可，受理号CXHL2401453。公示信息显示，药品“HSK44459片”适应症：特应性皮炎。上海海思盛诺医药科技有限公司，成立于2022年，位于上海市，是一家以从事研究和试验发展为主的企业。企业注册资本100万人民币，实缴资本100万人民币。通过天眼查大数据分析，上海海思盛诺医药科技有限公司。主要股东信息显示，上海海思盛诺医药科技有限公司由海思科医药集团股份有限公司持股100%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/11121848651300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","159938","BK1515","BK1583","BK1141","BK1161","BK1574","09939","BK1576"],"gpt_icon":0},{"id":"2518759077","title":"华测检测：医药医学是华测重点布局的领域之一提供全链条服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2518759077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518759077?lang=zh_cn&edition=full","pubTime":"2025-03-11 12:06","pubTimestamp":1741665977,"startTime":"0","endTime":"0","summary":"证券之星消息，华测检测03月11日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100018923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","300012","BK1161","BK0132","BK1574","LU2460026573.USD","09939","BK0159","BK0221","LU1146622755.USD","159938","LU1820825898.SGD"],"gpt_icon":0},{"id":"2518756540","title":"奥克股份：公司医药级聚乙二醇产品质量领先，全系产品通过了EXCiPACT认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2518756540","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518756540?lang=zh_cn&edition=full","pubTime":"2025-03-11 11:37","pubTimestamp":1741664240,"startTime":"0","endTime":"0","summary":"证券之星消息，奥克股份(300082)03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：聚乙二醇作为脑机手术必须材料，要求生产厂家有高纯度以及相关药用资质，请问公司在聚乙二醇纯度技术以及药用资质方面状况如何？奥克股份回复：尊敬的投资者，您好！公司医药级聚乙二醇产品质量领先，全系产品通过了EXCiPACT认证，被广泛应用于注射剂、局部用制剂、眼用制剂、口服及直肠用制剂等多种药物剂型，暂不涉及脑机领域。感谢您的关注！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100017341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0070","BK0155","BK0201","BK1515","BK1574","BK0028","159938","300082","09939","BK0229"],"gpt_icon":0},{"id":"2518340927","title":"同源康医药-B盘中异动 急速下跌5.20%报33.700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518340927","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518340927?lang=zh_cn&edition=full","pubTime":"2025-03-11 09:33","pubTimestamp":1741656782,"startTime":"0","endTime":"0","summary":"2025年03月11日早盘09时33分，同源康医药-B股票出现异动，股价快速下挫5.20%。截至发稿，该股报33.700港元/股，成交量3.25万股，换手率0.01%，振幅5.34%。资金方面，该股资金流入7.0875万港元，流出61.395万港元。同源康医药-B股票所在的生物技术行业中，整体跌幅为0.08%。同源康医药-B公司简介：浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。TY-2136b为自主研发、口服ROS1/NTRK抑制剂,用于治疗实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311093302abf4841b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311093302abf4841b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","09939","BK1574","02410","BK1161"],"gpt_icon":0},{"id":"2518980270","title":"“头对头”击败阿斯利康，同源康医药选择的小众赛道，尚无专属获批药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2518980270","media":"钛媒体","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518980270?lang=zh_cn&edition=full","pubTime":"2025-03-11 00:00","pubTimestamp":1741622432,"startTime":"0","endTime":"0","summary":"同源康医药计划于近期提交卡达沙的NDA上市申请。根据同源康医药招股书介绍，卡达沙有两大单药研究方向：一是EGFR突变NSCLC脑转移，即癌细胞从其原发部位扩散到大脑，这一适应症目前尚无专属获批药物。目前，同源康医药公布了该实验的积极“头对头”数据。可见，同源康药业选择的小众赛道上，也不乏更多追赶者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031100003998a2bcda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031100003998a2bcda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","BK1574","BK1515","02410"],"gpt_icon":0},{"id":"2518527194","title":"“头对头”击败肺癌药物明星品种？同源康医药早盘一度涨超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518527194","media":"澎湃","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518527194?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:18","pubTimestamp":1741616326,"startTime":"0","endTime":"0","summary":"同源康医药 视觉中国 资料图3月10日，浙江同源康医药股份有限公司早盘最高涨超50%，收涨16.18%。同源康医药称，针对EGFR突变肺癌脑转移适应证，TY-9591是全球首个且唯一单药头对头奥希替尼临床研究中显示出显著优于奥希替尼的药物。“头对头”挑战这一重磅品种，同源康医药最新的积极数据自然引发全行业关注。官网资料显示，同源康医药成立于2017年11月，2024年8月在港股上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223049abf31290&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223049abf31290&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1574","BK1515","BK1161","02410"],"gpt_icon":0},{"id":"2518322934","title":"吉林敖东：公司核心业务与吉林省“医药强省”战略方向一致","url":"https://stock-news.laohu8.com/highlight/detail?id=2518322934","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518322934?lang=zh_cn&edition=full","pubTime":"2025-03-10 20:51","pubTimestamp":1741611072,"startTime":"0","endTime":"0","summary":"证券之星消息，吉林敖东03月09日在投资者关系平台上答复投资者关心的问题。证监会发布“积极支持符合条件的吉林省企业通过首发和再融资募集资金，利用资本市场做大做强，充分发挥资本市场对吉林省经济发展的支持作用。”公司核心业务涵盖中药、化药、生物制药及参业资源开发，与吉林省“医药强省”战略方向一致。具体情况请以公司在指定媒体披露的信息为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000031705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0239","BK1161","BK0074","BK0012","BK0028","BK0188","BK1574","BK0086","000623","09939","159938","BK0201"],"gpt_icon":0},{"id":"2518218659","title":"【海王生物：NEP018片获药物临床试验批准】海王生物公告，全资子公司海王医药研究院的NEP018片近日获得国家药监局核准签发的《药物临床试验批准通知书》。通知书指出，经审查，NEP018片临床试验申请符合药品注册有关要求，同意其在晚期恶性实体瘤中开展临床试验。NEP018片是海王医药研究院自主研发的新型肿瘤靶向小分子激酶抑制剂，对设计靶点有良好选择抑制活性，针对胃肠道肿瘤具有良好的抑制作用。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518218659","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518218659?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:27","pubTimestamp":1741595279,"startTime":"0","endTime":"0","summary":"海王生物公告，全资子公司海王医药研究院的NEP018片近日获得国家药监局核准签发的《药物临床试验批准通知书》。通知书指出，经审查，NEP018片临床试验申请符合药品注册有关要求，同意其在晚期恶性实体瘤中开展临床试验。NEP018片是海王医药研究院自主研发的新型肿瘤靶向小分子激酶抑制剂，对设计靶点有良好选择抑制活性，针对胃肠道肿瘤具有良好的抑制作用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/10162748625635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","000078","BK1161","BK1141","BK0028","03347","BK0060","BK0188","BK1574","BK1576","BK1583","BK0209","09939","159938","BK0168"],"gpt_icon":0},{"id":"2518210397","title":"华昊中天医药-B03月10日主力净流出15万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2518210397","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518210397?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:16","pubTimestamp":1741594570,"startTime":"0","endTime":"0","summary":"03月10日, 华昊中天医药-B股价跌19.04%，报收12.50元，成交金额363万元，换手率0.13%，振幅15.03%，量比2.78。华昊中天医药-B今日主力资金净流出15万元，上一交易日主力净流出0万元。该股近5个交易日下跌22.26%，主力资金累计净流出15万元；近20日主力资金累计净流入249万元，其中净流入天数为1日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310170118a269ba8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310170118a269ba8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02563","BK1515","BK1161","BK1574","09939"],"gpt_icon":0},{"id":"2518219211","title":"开拓药业-B03月10日主力净流出32万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2518219211","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518219211?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:15","pubTimestamp":1741594526,"startTime":"0","endTime":"0","summary":"03月10日, 开拓药业-B股价跌2.59%，报收1.13元，成交金额177万元，换手率0.35%，振幅6.90%，量比0.83。开拓药业-B今日主力资金净流出32万元，上一交易日主力净流入11万元。该股近5个交易日上涨4.63%，主力资金累计净流出21万元；近20日主力资金累计净流出335万元，其中净流出天数为7日。该股主力净额占比0.06%，港股市场排名2533/2655。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310165645abf2918b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310165645abf2918b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09939","BK1515"],"gpt_icon":0},{"id":"2518297065","title":"健康元：公司接入DeepSeek全面推进AI在医药全链条的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2518297065","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518297065?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:07","pubTimestamp":1741594032,"startTime":"0","endTime":"0","summary":"相当一部分重复性的工作可以通过应用AI增强效率，具体降低的比例尚未确定，因为这取决于多种因素，包括技术应用的深度和广度，以及市场环境的变化等。感谢您对公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000019698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","09939","600380"],"gpt_icon":0},{"id":"2518993712","title":"“能源+医药”双线布局，美锦能源“跨界救火”迎涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2518993712","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518993712?lang=zh_cn&edition=full","pubTime":"2025-03-10 15:38","pubTimestamp":1741592307,"startTime":"0","endTime":"0","summary":"双主业?","market":"us","thumbnail":"https://img3.gelonghui.com/93390-509772b6-a74f-47fc-874a-23c6f1e9d5b2.jpg?guru_height=853&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/93390-509772b6-a74f-47fc-874a-23c6f1e9d5b2.jpg?guru_height=853&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1873230","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["000723","BK0275","BK1515","BK1574","09939","BK1161"],"gpt_icon":0},{"id":"2518329963","title":"3月10日润达医疗涨停分析：医药商业，医疗耗材供应链SPD，互联网医疗概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2518329963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518329963?lang=zh_cn&edition=full","pubTime":"2025-03-10 15:31","pubTimestamp":1741591886,"startTime":"0","endTime":"0","summary":"证券之星消息，润达医疗3月10日涨停收盘，收盘价22.84元。该股于9点25分涨停，未打开涨停，截止收盘封单资金为8.69亿元，占其流通市值6.3%。近5日资金流向一览见下表：该股为医药商业，医疗耗材供应链SPD，互联网医疗概念热股，当日医药商业概念上涨3.47%，医疗耗材供应链SPD概念上涨3.34%，互联网医疗概念上涨2.01%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000014757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","603108","BK1574","BK1161","BK1515","159891","159938","BK0250"],"gpt_icon":0},{"id":"2518299376","title":"A股收评：三大指数小幅调整，创业板指跌0.25%，培育钻石、医药商业板块爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2518299376","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518299376?lang=zh_cn&edition=full","pubTime":"2025-03-10 15:27","pubTimestamp":1741591671,"startTime":"0","endTime":"0","summary":"沪深两市全天成交额1.51万亿，较上个交易日缩量3126亿","market":"sg","thumbnail":"https://img3.gelonghui.com/a48cd-6da2875c-c1af-4256-a34f-0987cf96fa90.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a48cd-6da2875c-c1af-4256-a34f-0987cf96fa90.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1873151","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["09939","BK1574","BK1161","BK1515"],"gpt_icon":0},{"id":"2518645762","title":"A股医药商业板块午后活跃，老百姓涨停，海王生物、健之佳、人民同泰、漱玉平民、益丰药房等涨幅靠前。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518645762","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518645762?lang=zh_cn&edition=full","pubTime":"2025-03-10 13:36","pubTimestamp":1741584961,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1064131003.USD","603939","BK0060","600829","LU2148510915.USD","LU2460026573.USD","399300","603883","159982","LU1064130708.USD","09939","BK0209","BK1161","BK0188","605266","BK0250","BK1574","301017","BK0168","000078","159938","BK0028","LU2488822045.USD","BK1515"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0.0463},{"period":"1month","weight":0.2418},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.3951},{"period":"1year","weight":0.1649},{"period":"ytd","weight":0.1649}],"compareEarnings":[{"period":"1week","weight":0.0338},{"period":"1month","weight":0.1254},{"period":"3month","weight":0.1709},{"period":"6month","weight":0.3901},{"period":"1year","weight":0.4543},{"period":"ytd","weight":0.1856}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家临床阶段新药开发商，专注于研究癌症药物及其他雄激素受体（AR）相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌（mCRPC）的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.063412},{"month":2,"riseRate":0.8,"avgChangeRate":0.219909},{"month":3,"riseRate":0.4,"avgChangeRate":0.053823},{"month":4,"riseRate":0.75,"avgChangeRate":0.545629},{"month":5,"riseRate":0.5,"avgChangeRate":0.006555},{"month":6,"riseRate":0.2,"avgChangeRate":-0.08997},{"month":7,"riseRate":0.6,"avgChangeRate":0.020249},{"month":8,"riseRate":0.2,"avgChangeRate":-0.059234},{"month":9,"riseRate":0.2,"avgChangeRate":-0.170155},{"month":10,"riseRate":0.2,"avgChangeRate":-0.081213},{"month":11,"riseRate":0.6,"avgChangeRate":0.071209},{"month":12,"riseRate":0.2,"avgChangeRate":-0.215118}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.5","shortVersion":"4.31.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}